Top Page
Polynovo
(OTC:PNV)
Polynovo (PNV) vs. iShares MSCI Australia ETF (EWA)
Polynovo Business Overview & Revenue Model
Polynovo Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 127.26M | 127.24M | 103.19M | 65.24M | 41.44M | 29.16M |
| Gross Profit | 76.45M | 122.05M | 97.71M | 19.33M | 16.23M | 7.83M |
| EBITDA | 10.75M | 10.45M | 4.59M | -2.71M | 658.24K | -3.41M |
| Net Income | 13.21M | 13.21M | 5.26M | -4.92M | -1.19M | -4.61M |
Balance Sheet | ||||||
| Total Assets | 127.41M | 127.41M | 108.72M | 92.62M | 34.97M | 38.34M |
| Cash, Cash Equivalents and Short-Term Investments | 33.59M | 33.59M | 45.96M | 46.90M | 6.15M | 7.74M |
| Total Debt | 17.14M | 17.14M | 15.38M | 16.04M | 10.99M | 10.00M |
| Total Liabilities | 44.15M | 44.15M | 36.60M | 27.24M | 17.26M | 15.99M |
| Stockholders Equity | 83.26M | 83.26M | 72.12M | 65.38M | 17.72M | 22.35M |
Cash Flow | ||||||
| Free Cash Flow | -10.68M | -10.78M | 786.00K | -7.46M | -2.55M | -3.82M |
| Operating Cash Flow | 3.25M | 3.15M | 3.68M | -5.93M | -2.06M | -248.74K |
| Investing Cash Flow | -13.93M | -13.22M | -1.49M | -1.53M | 5.86M | -3.57M |
| Financing Cash Flow | -2.39M | -2.39M | -3.17M | 48.06M | -5.39M | -70.37K |
Polynovo Technical Analysis
Polynovo Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $157.09M | -45.00 | -7.26% | ― | 21.65% | 81.40% | |
54 Neutral | AU$846.28M | 64.14 | 16.49% | ― | 23.31% | 151.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$104.47M | -7.78 | -31.98% | ― | 34.20% | -23.90% | |
49 Neutral | AU$263.95M | -159.38 | -2.01% | ― | 16.93% | 76.47% | |
47 Neutral | AU$2.47B | -65.16 | -44.49% | ― | 55.91% | 22.60% | |
44 Neutral | AU$171.94M | -16.13 | -70.55% | ― | ― | -257.32% |
Polynovo Corporate Events
PolyNovo Limited has appointed Amy Demediuk as Company Secretary and General Counsel, effective February 2026. Ms. Demediuk brings extensive legal and compliance experience from her previous roles at CSL, enhancing PolyNovo’s leadership team as it seeks to continue its growth trajectory. Her appointment is expected to add significant value to the company’s operations and stakeholder engagement.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$1.62 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited presented at the Bell Potter Healthcare Conference, highlighting its position in the healthcare industry. The company is known for its innovative medical solutions, particularly in the field of advanced wound care. The presentation was intended for general information purposes and emphasized that the information provided is subject to change. PolyNovo disclaimed any liability for the accuracy or completeness of the information, and the presentation did not constitute an offer or recommendation for investment.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
At the Annual General Meeting held on October 28, 2025, PolyNovo Limited successfully passed several key resolutions, including the re-election of directors Leon Hoare and David Williams, and the election of Robert Douglas as a director. The adoption of the remuneration report and approval of non-executive directors’ fees were also carried. These outcomes reflect strong shareholder support and are expected to positively impact the company’s governance and strategic direction.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo has reported a strong financial year with significant growth in commercial sales and regulatory clearances, expanding its market reach to 46 countries. The company is poised for further growth with the upcoming commercialization of new products and anticipated pricing reforms, supported by a robust cash position and strategic leadership changes.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has announced the resignation of its Chairman, David Williams, with Leon Hoare stepping in as the new Chair. This leadership change aligns with the company’s board succession plans and governance review, ensuring a smooth transition without disrupting operations or strategic direction. Under Williams’ leadership, PolyNovo transformed into a global medical technology company, achieving record sales growth and expanding its presence to 46 countries. The company remains committed to its business strategy and growth plans.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Polynovo Limited announced the appointment of Robert Douglas as a director, effective October 14, 2025. This appointment is part of the company’s strategic efforts to strengthen its leadership team and enhance its market position in the medical technology sector. The announcement does not indicate any current securities or contract interests held by the new director, suggesting a fresh start in his role.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has announced the appointment of Mr. Robert Douglas as a new Non-Executive Director, with a resolution for his election to be proposed at the upcoming Annual General Meeting. Mr. Douglas brings extensive experience from his previous role as Global Chief Operating Officer at ResMed, and his expertise is expected to enhance the board’s skillset and governance, benefiting the company and its stakeholders.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has appointed Bruce Peatey as the new CEO, effective December 1, 2025. With extensive experience in healthcare, medical devices, and biotechnology, Peatey brings valuable skills in managing quality and regulatory functions, strategic business development, and market expansion. His leadership is expected to drive PolyNovo’s growth into new markets and enhance its international presence, particularly in the outpatient sector. The company anticipates that Peatey’s expertise and established relationships in the industry will inform its strategic approach to distribution in the US and key international markets.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has appointed Mr. Robert Douglas as a Non-Executive Director to its Board. Mr. Douglas brings over 35 years of experience in medical device technology and public company governance, with a strong background in digital health and international business expansion. His previous roles at ResMed and current position with Globus Medical highlight his expertise in patient data management and cloud technology, which are expected to benefit PolyNovo’s strategic growth and innovation efforts.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$1.62 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.